肢端雀斑样黑素瘤与其他皮肤黑素瘤亚型患者的前哨淋巴结活检阳性率
基于美国国家癌症数据库2012至2015年诊断的60148例AJCC第8版临床I至II期黑素瘤患者的回顾性队列研究,其中959例为肢端雀斑样黑素瘤(ALM)。多变量逻辑回归显示ALM与前哨淋巴结(SLN)阳性风险独立相关,相比浅表扩散型黑素瘤的比值比为1.91(95%CI 1.59-2.28)。ALM临床IB期和II期的SLN阳性率分别为18.39%(95%CI 13.82%-24.03%)和39.53%(95%CI 34.98%-44.26%)。
要点
- ALM是SLN阳性风险最高的黑素瘤亚型,相比浅表扩散型比值比为1.91(95%CI 1.59-2.28)。
- ALM临床IB期SLN阳性率为18.39%(95%CI 13.82%-24.03%),II期为39.53%(95%CI 34.98%-44.26%)。
- 作者认为应对所有临床IB和II期ALM患者鼓励进行前哨淋巴结活检,并给予关于区域转移风险较高的适当咨询。
核心结论
- 在这项队列研究中,ALM与SLN阳性独立相关,且在临床IB和II期具有相对较高的阳性率。
- 作者认为这提示应对所有临床IB和II期ALM患者鼓励进行前哨淋巴结活检,并应给予此类患者关于其癌症区域转移风险较高的适当咨询。
- 作者指出需要未来在更大队列中开展工作以阐明临床IA期ALM的SLN阳性风险。
研究设计与样本
- 美国国家癌症数据库(NCDB)纳入美国癌症委员会认证机构的所有可报告病例,约占美国所有新诊断黑素瘤病例的50%。
- 本回顾性队列研究纳入NCDB中2012年至2015年诊断的AJCC第8版临床I至II期黑素瘤病例。
- 分析在2021年4月至2021年9月间进行。
- 暴露因素为黑素瘤组织病理学亚型,主要结局指标为前哨淋巴结状态。
主要发现
- 共识别出60148例恶性黑素瘤患者,其中959例为ALM亚型。
- 队列中25550例(42.5%)为女性,平均(SD)年龄为64(16)岁。
- 控制人口学和组织病理学特征的多变量逻辑回归显示,ALM在纳入的亚型中与SLN阳性最高风险独立相关(对比浅表扩散型黑素瘤:比值比1.91;95%CI 1.59-2.28)。
- 按AJCC临床分期进行的亚组分析显示,ALM在IB期和II期疾病中均与SLN阳性最高风险独立相关。
- 临床IB期ALM患者的SLN阳性率为18.39%(95%CI 13.82%-24.03%),临床II期ALM患者的SLN阳性率为39.53%(95%CI 34.98%-44.26%)。
临床怎么用
- 作者认为应对所有临床IB和II期ALM患者鼓励进行前哨淋巴结活检,并应给予此类患者关于其癌症区域转移风险较高的适当咨询。
- 作者指出未来需要更大队列的工作来阐明临床IA期ALM的SLN阳性风险。
局限性
- 作者指出需要未来在更大队列中开展工作以阐明临床IA期ALM的SLN阳性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acral lentiginous melanoma (ALM) is a rare subtype of malignant melanoma typically occurring on the palmar and plantar surfaces. Although it has distinctive genetic, prognostic, and behavioral characteristics relative to cutaneous melanomas overall, owing to its rarity, treatment is largely guided by data extrapolated from more common subtypes. Although sentinel lymph node (SLN) status has been shown to be a significant prognostic factor for ALM, the independent effect of ALM-subtype disease on the likelihood of SLN positivity and the stage-specific positivity rates for ALM are not well characterized. OBJECTIVE: To evaluate the association of ALM with SLN status as well as to characterize the clinical stage-specific rates of SLN positivity for ALM based on the AJCC Cancer Staging Manual, 8th edition (AJCC-8). DESIGN, SETTING, AND PARTICIPANTS: The National Cancer Database (NCDB) includes all reportable cases from Commission on Cancer accredited facilities and represents approximately 50% of all newly diagnosed melanoma cases in the US. This retrospective cohort study included cases of AJCC-8 clinical stage I to II melanomas from the NCDB diagnosed from 2012 to 2015. The analysis took place between April 2021 and September 2021. EXPOSURES: Melanoma histopathologic subtype. MAIN OUTCOMES AND MEASURES: Sentinel lymph node status. RESULTS: We identified 60 148 patients with malignant melanomas, 959 of whom had ALM-subtype disease. Among patients in the cohort, 25 550 (42.5%) were women and the mean (SD) age was 64 (16) years. Multivariable logistic regression controlling for demographic and histopathologic characteristics revealed that ALM was independently associated with the highest risk for SLN positivity among included subtypes (vs superficial spreading melanoma: odds ratio, 1.91; 95% CI, 1.59-2.28). Subgroup analysis by AJCC clinical stage demonstrated that ALM was independently associated with the highest risk for SLN positivity for both stage IB and II disease. The rate of SLN positivity for patients with stage IB and II ALM was 18.39% (95% CI, 13.82%-24.03%) and 39.53% (34.98%-44.26%), respectively. CONCLUSIONS AND RELEVANCE: In this cohort study ALM was independently associated with SLN positivity and had relatively high positivity rates at clinical stage IB and II. This suggests that SLNB should be encouraged for all patients with clinical stage IB and II ALM, and such patients should receive appropriate counseling about the higher regional metastatic risk of their cancers. Future work with a larger cohort is required to elucidate the risk of SLN positivity for stage IA ALM.
引用
- Cheraghlou S, Ugwu N, Girardi M, et al. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatol. 2022. PMID: 34878492. doi:10.1001/jamadermatol.2021.4812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。